Context Therapeutics Inc
Research Context Therapeutics Inc (CNTX) on Bullrun: market cap USD 39.97M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCNTX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 39.97M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 14.56M
- Free cash flow-USD 11.54M
Valuation Snapshot
latest market cap is USD 39.97M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 36.12M | -USD 26.42M | n/a | -0.38 | USD 66.00M | USD 112.06K | USD 60.47M |
| FY2024 | USD 0 | -USD 26.73M | -USD 14.56M | n/a | -0.46 | USD 94.43M | USD 219.38K | USD 95.27M |
| FY2023 | n/a | -USD 23.96M | -USD 21.05M | n/a | -1.5 | USD 14.45M | USD 0 | USD 11.87M |
| FY2022 | n/a | -USD 14.84M | -USD 13.59M | n/a | -0.93 | USD 35.50M | USD 55.08K | USD 34.76M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 39.97M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 135.06M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 94.19M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 18.04M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 10.38M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 42.47M | n/a | n/a | n/a |
About Context Therapeutics Inc
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Context Therapeutics Inc's market cap?
Context Therapeutics Inc's market capitalization is USD 39.97M.
What does Context Therapeutics Inc do?
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.